BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36017704)

  • 1. Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study.
    Zheng H; Li H; Wang Y; Li Z; Hu B; Li X; Fu L; Hu H; Nie Z; Zhao B; Wei D; Karlson BW; Bots ML; Meng X; Chen Y; Wang Y;
    Stroke; 2022 Oct; 53(10):3004-3013. PubMed ID: 36017704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
    Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
    JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study.
    Crouse JR; Bots ML; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Raichlen JS;
    Eur J Cardiovasc Prev Rehabil; 2010 Apr; 17(2):223-9. PubMed ID: 20038840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis-design, rationale, and methodology of the METEOR-China study.
    Wang Y; Wang A; Li H; Li Z; Hu B; Li X; Zheng H; Fu L; Hu H; Nie Z; Qin Y; Zhao B; Wei D; Karlson BW; Bots ML; Chen Y; Wang Y
    Trials; 2020 Nov; 21(1):921. PubMed ID: 33176842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study.
    Bots ML; Palmer MK; Dogan S; Plantinga Y; Raichlen JS; Evans GW; O'Leary DH; Grobbee DE; Crouse JR;
    J Intern Med; 2009 Jun; 265(6):698-707. PubMed ID: 19298496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis--the rationale and methodology of the METEOR study.
    Crouse JR; Grobbee DE; O'Leary DH; Bots ML; Evans GW; Palmer MK; Riley WA; Raichlen JS;
    Cardiovasc Drugs Ther; 2004 May; 18(3):231-8. PubMed ID: 15229392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extensive or restricted ultrasound protocols to measure carotid intima-media thickness: analysis of completeness rates and impact on observed rates of change over time.
    Peters SA; den Ruijter HM; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Evans GW; Raichlen JS; Bots ML;
    J Am Soc Echocardiogr; 2012 Jan; 25(1):91-100. PubMed ID: 21982737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manual or semi-automated edge detection of the maximal far wall common carotid intima-media thickness: a direct comparison.
    Peters SA; den Ruijter HM; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Evans GW; Raichlen JS; Lind L; Bots ML;
    J Intern Med; 2012 Mar; 271(3):247-56. PubMed ID: 21726301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Algorithms to measure carotid intima-media thickness in trials: a comparison of reproducibility, rate of progression and treatment effect.
    Dogan S; Plantinga Y; Crouse JR; Evans GW; Raichlen JS; O'Leary DH; Palmer MK; Grobbee DE; Bots ML;
    J Hypertens; 2011 Nov; 29(11):2181-93. PubMed ID: 21918474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rosuvastatin on the echolucency of the common carotid intima-media in low-risk individuals: the METEOR trial.
    Lind L; Peters SA; den Ruijter HM; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Evans GW; Raichlen JS; Bots ML;
    J Am Soc Echocardiogr; 2012 Oct; 25(10):1120-1127.e1. PubMed ID: 22884641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of atherosclerosis in patients living with HIV.
    De Lorenzo F; Boffito M; Collot-Teixeira S; Gazzard B; McGregor JL; Shotliff K; Xiao H
    Vasc Health Risk Manag; 2009; 5(1):287-300. PubMed ID: 19436663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 2-year treatment with low-dose rosuvastatin on intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease.
    Riccioni G; Cipollone F; Santovito D; Scotti L; D'Orazio N; Mezzetti A; Bucciarelli T
    Expert Opin Pharmacother; 2011 Dec; 12(17):2599-604. PubMed ID: 21999752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. METEOR Trial Reports on the Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical Atherosclerosis.
    Haddad RM; Ballantyne CM
    Phys Sportsmed; 2010 Jun; 38(2):180-2. PubMed ID: 20631478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin reduces intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease: the Asymptomatic Carotid Atherosclerotic Disease in Manfredonia (ACADIM) Study.
    Riccioni G; Bazzano LA; Bucciarelli T; Mancini B; di Ilio E; D'Orazio N
    Expert Opin Pharmacother; 2008 Oct; 9(14):2403-8. PubMed ID: 18778179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time: the METEOR study.
    Peters SA; Dogan S; Meijer R; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Evans GW; Raichlen JS; Bots ML
    J Atheroscler Thromb; 2011; 18(9):784-95. PubMed ID: 21617330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologically implausible carotid intima-media thickness measurement values: effects on rate of change over time.
    Peters SA; den Ruijter HM; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Evans GW; Raichlen JS; Bots ML;
    Curr Med Res Opin; 2012 Jun; 28(6):891-9. PubMed ID: 22536884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein lowering with rosuvastatin in the METEOR study.
    Peters SA; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Raichlen JS; Bots ML
    J Intern Med; 2010 Aug; 268(2):155-61. PubMed ID: 20412373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study.
    Nohara R; Daida H; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yamazaki T; Yokoi H; Yoshida M;
    Circ J; 2012; 76(1):221-9. PubMed ID: 22094911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact on the carotid intima-medial thickness and safety of rosuvastatin in Chinese patients with carotid atherosclerosis: a meta-analysis].
    Feng X; Zhang J; Liu M; Li X
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Mar; 42(3):247-53. PubMed ID: 24831484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk.
    Calza L; Manfredi R; Colangeli V; Trapani FF; Salvadori C; Magistrelli E; Danese I; Verucchi G; Serra C; Viale P
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):547-56. PubMed ID: 23098891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.